Reddit Posts
LCPN - Thoughts on stagnation?
14 APRIL 2026 , WHAT ARE THE BIGGEST LOSERS PRE-MARKET AND WHY ?
WHAT ARE THE BIGGEST LOSERS PRE-MARKET AND WHY ? >>>>>
02 APRIL 2026 , WHAT ARE THE BIGGEST LOSERS TODAY AND WHY
LPCN MUST SEE LOW FLOATER
Watchlist for Friday Jan 2nd ๐
LPCN gets FDA approval - and is beaten down -25% in pre-market. WTF?
[LPCN] FDA approves TLANDO (testosterone undecanoate) oral treatment for testosterone replacement therapy
Anyone playing Lipocine (LPCN) for the FDA approval decision Monday?
How do you guys feel about LPCNโs future?
$LPCN Positive PH3 results - something to checkout if youโre into biotechs
BLCT vs SNMP vs AQMS vs VGFC vs LPCN
An Illustration of Five Different Bullish Positions at Different Fills
$LPCN some bigwig really doesnโt want this to run. Hate this manipulation smh
Looking for a bear opinion on $LPCN
Anyone notice how most of the top DD posted on here this year, came around the peak of the stock and the stock has only fallen since?
LPCN & QTNT: Two HIGH RISK Penny Stocks With Better than Average Potential
Mentions
LPCN has an FDA guidance meeting this quarter. Post hoc analysis of their phase 3 topline miss last April looks like it may have been a problem with one of the site locations rather than a problem with the drug. The KOL event in June available on their website has the details We'll find out relatively soon if they had enough evidence to convince the FDA or not. Not investment advice, just an event that could have an impact on the company value one way or the other near term.
Jumping on the Low T bandwagon by going balls deep in LPCN. US military will buy all testosterone boosting pharmaceuticals and have the most alpha chad army of all time!
LPCN's pipeline is now severely undervalued and it has an impressive cash runway, but I don't think any other candidate drugs are far enough ahead for it to be de-risked re: offerings. I'll be keeping it on my radar.
LPCN looks interesting. While its lead pipeline drug failed (abysmally), another drug in development (LPCN 1107) offers a counter to the economic impact of malnutrition.
No love for LPCN and their phase 3 PPD data readout coming in early April. They clarified that timeline in yesterday's press release for their annual report.
LPCN๐๐๐
$LPCN announced last patient last visit in their phase 3 safety and efficacy postpartum depression trial. I think all the interim updates they've given in their press releases regarding safety have been positive. The drug is an oral version of the IV drug Zulresso, which had faster onset, higher efficacy and a shorter treatment duration than Zurzuvae, but required a 60 hour stay in the hospital hooked up to an IV. Lipocine's market cap is only around 45-50m, BioGen reported that Zurzuvae revenue was $66m in Q4 2025. If the efficacy of Lipocine's oral brexanolone matches that of the IV brexanolone, then Lipocine has a rapid onset (hours vs days) shorter treatment duration (48 hours vs 14 days) more effective oral outpatient treatment than Zulresso. It is also on a 505(b)(2) regulatory pathway since it is the same molecule as the already approved IV treatment. The company's guidance in their earlier press releases was that results are expected early Q2, but I think that's a conservative estimate. Always do your own due diligence, and if anything above is wrong please let me know. I recommend their corporate presentation for their pipeline details and their press releases for the latest trial information.
LPCN ๐๐๐
LPCN ๐๐๐
LPCN ๐๐๐
LPCN๐๐๐
Its not listed in the chart for this thread, but LPCN has a phase 3 safety and efficacy data readout coming early Q2 2026 for their postpartum depression drug. Its on a 505(b)(2) regulatory pathway. In a nutshell their drug delivery technology allowed them to take the molecule (brexanolone) from the IV drug Zulresso and administer it orally. Their drug already met standard bioequivalence criteria to IV Brexanolone in earlier studies, and their recent press releases have reported positive safety results through patient dosing as well. If the data showe oral brexanolone has the same efficacy as the IV brexanolone then this drug would be a shorter treatment duration (48 hrs vs 14 days), faster onset (hours vs days), more effective drug than Zurzuvae currently on the market. We won't know that until the resilts of this safety and efficacy trial come out in several weeks, but its an opportunity I've been eying for a long time. Always do your own dd, let me know if anything is inaccurate. This is a 45m company with an exciting opportunity in a market that is already generating 66m in quarterly revenue for Zurzuvae. I recommend their corporate presentation and January press releases for research and I believe their earnings report is coming out in early March.
LPCN๐๐๐
LPCN absolutely crushing it this week! (And for the last month+)
LPCN - Just watch the graph...
LPCN as usual - recommend it from 4.1 not its 8.05 without noise or approval. this thing gonna fly
Two weeks ago i told u in a post about LPCN. 60% and still going..
LPCN, already up 50% in the last week
This run is related to their PPD drug that is nearing the end of it's phase 3 trial. Their press release in mid december announced they reached 80% enrollment and we'll get their 2nd DSMB safety update in mid January. If the enrollment pace continues at a similar rate they could be announcing complete enrollment in that same press release. The topline data is expected 2Q 2026, and as long as the data warrants it they'll be ready to file the NDA before the end of 2026. They have enough cash to get through the topline results and at least until Nov 2026 according to their last earnings report, but I don't think they have enough tonself fund the NDA. Whether they raise cash or find funding through a business development deal is unknown at this point. 1148 is an interesting asset, but their phase 2 had limited patiet population, I expect the FDA will require a phase 3 and more data. They have other interesting drugs in their pipeline for epilepsy, treatment resistant depression, and an adjunct therapy for glp-1's. Those drugs also need FDA input before the company can start phase 2 POV studies, and of course those aren't free so they'll need to prioritize how they're spending their cash. The point is, their lead CNS asset, LPCN 1154 aka Brlizio is nearing the end of its phase 3 trial. It's a faster acting (hours instead of days), shorter duration (48 hours vs 14 days) treatment than zurzuvae, which is the only oral ppd treatment currently on the market. Always do your own DD. If you find i'm wrong on any of this please post a correction, I'm just an amateur investor doing my best to share my understanding of what's happening with this company. Good luck with your investments.
Keep telling you since last week. $LPCN
LPCN running good. Look at the post I posted yesterday
I can give you other pharma stocks at the bottom; GNPX, LPCN
LPCN, worth looking into as a long term play, just an undervalued phase 2 pharma
!BanBet LPCN to hit over 5.50 by June
$LPCN...Epic squeeze incoming...shorts dog piling...low float and positive Phase 2 data release...
LPCN, I think there topline data readout from their phase 2 liver cirrhosis therapy trial comes out tomorrow (They've said by the end of the quarter). Historically they've had a spike and then sell the news on their catalysts.
Let's make America great again LOL, LPCN to the moooooon!! ๐๐บ๐ธ๐ AMC and GME still a win. Good luck friends ๐
๐ฐ๐ฐ๐ฐGet new daily runners and watchlist in our app! #premarket #watchlist 07/27 $MNK - old news+big volume(+50%), $CTCX - Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company (+50%) $LPCN - Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis (+36%), $CLS - Earnings (+28%) https://preview.redd.it/zqyo5fxy4ieb1.jpeg?width=576&format=pjpg&auto=webp&s=da9e1db525c280c7b57a1de7912be50e24104203
๐ฐ๐ฐ๐ฐGet new daily runners and watchlist in our app! #premarket #watchlist 07/27 $MNK - old news+big volume(+50%), $CTCX - Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company (+50%) $LPCN - Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis (+36%), $CLS - Earnings (+28%) https://preview.redd.it/qr4jg41w4ieb1.jpeg?width=576&format=pjpg&auto=webp&s=2055ccfeabc5832d4f6c565374e0953f5b953579
WTF happened with LPCN?
Thoughts for LPCN over the weekend? I bought at .53
LPCN - Small bio-tech with great financials, income from already release products, and others in the pipeline. Lots of room for growth!
Hey /u/38931841Hz - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BOXL LPCN RKDA AQB OGEN FTFT EVGN JVA EKSO SFT. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
To be fair my small cap bio position in LPCN is up 8% today
$LPCN is shown at +23% pre-market (after taking a -11% hit yesterday, on earnings which were not great). I wonder if it's just a pre-market artifact or if it will last (can't find any news justifying this bump)
LPCN 4.32% US ER 7.55%.CL SK 3.54% By very green I meant very little red .
LPCN 4.32% US ER 7.55%.CL SK 3.54% By very green I meant very little red .
Iโve been holding a few shares. I bought at 1.22 and sold at 2.15 but then got back in at .83. I also hold LPCN which also has a testosterone pill approved.
LPCN Iโm not giving up hope yet!
Take a look at LPCN, AIM, and a few others that tanked after positive reports/FDA updates. You have to fight the bears and shorts by staying long.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: LPCN. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
Buying up some LPCN. Itโs a steal at these prices.
IONQ + NVTS + RDW + LPCN + NILE . Red almost 3%
Not OP but I have my eye on LIAN, ACER, AKBA. I just got some LPCN which should do well once the deal with ATRS is official.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: LPCN LPCN. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: LPCN. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: LPCN. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: LPCN. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
LPCN: U.S. Food and Drug Administration ("FDA") has approved TLANDOโข (testosterone undecanoate), an oral treatment for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. Lipocine licensed the exclusive U.S. commercialization rights for TLANDOโข to Antares Pharma.
why is Lipocine $LPCN down now?
$LPCN Tlando tentative approval (yesterday): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208088Orig1s000TA_ltr.pdf
Bought LPCN + BGRY Added to CLSK
Two moves you might want to keep on your radar that have great potential: 1. โ $LPCN - LPCN new drug application for Tlando, an oral prodrug of testosterone containing testosterone undecanoate, on Monday, March 28. Tlando has received tentative approval from the FDA in December for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. 2. โ $AKBA - AKBA has a PDUFA date of Tuesday, March 29 for its NDA of vadadustat for treating anemia in chronic kidney disease patients. $LPCN already has a partner set up and is close relationship with the FDA for fast tracking other drugs. Donโt see how this first drug isnโt approved seeing as the FDA already granted tentative approval. $AKBA is what long term investors of the stock were waiting for since July of 2021. FDA approval looks likely but canโt say. $LPCN is a lot safer if a bet.
Two moves you might want to keep on your radar that have great potential: 1. $LPCN - LPCN new drug application for Tlando, an oral prodrug of testosterone containing testosterone undecanoate, on Monday, March 28. Tlando has received tentative approval from the FDA in December for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. 2. $AKBA - AKBA has a PDUFA date of Tuesday, March 29 for its NDA of vadadustat for treating anemia in chronic kidney disease patients. $LPCN already has a partner set up and is close relationship with the FDA for fast tracking other drugs. Donโt see how this first drug isnโt approved seeing as the FDA already granted tentative approval. $AKBA is what long term investors of the stock were waiting for since July of 2021. FDA approval looks likely but canโt say. $LPCN is a lot safer if a bet.
[LPCN await FDA approval](https://www.billionaireclubcollc.com/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-for-amylyx-biontech-earnings-and-more/)
Thinking of getting some LPCN.
Time to go balls deep on something balls related. LPCN (Lipocene) and ATRS (Antares Pharma) FDA approval decision due on Monday for their New Drug Application (NDA), but it has already been approved. Seems like a no brainer. Think with your balls guys. >FDA decision on TLANDO as oral testosterone replacement therapy in adult males for conditions associated with hypogonadism. >FDA granted tentative approval for Tlando on Dec.8, 2020 >Lipocine licensed the exclusive U.S. rights for TLANDO to Antares Pharma in Oct.2021 Tentative approval >"(also known as โTAโ) is a notification granted by the FDA if an ANDA meets the substantive requirements for approval, but cannot obtain final approval for marketing due to unexpired patents or exclusivities. From the Lipocene 10-K filing: >TLANDO has not received final approval and is not eligible for final approval to market in the U.S. until the expiration of the exclusivity period previously granted to Clarus Therapeutics, Inc. (โClarusโ) with respect to JATENZOยฎ, which expires on March 27, 2022. The FDA has affirmed to Antares the acceptance of the resubmission of the NDA for TLANDO filed on January 28, 2022. The FDA has designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022 under the Prescription Drug User Fee Act (PDUFA). So hoping Monday for a quick earner on the news. Hope to see either or both on the Finviz homepage Monday open. Heavily weighted towards LPCN since they seem to be the ones making all the licensing money, and $1.85 right now. ATRS is about $4.06. There has been some upward momentum of late, so guessing a lot of people have been filling their boots awaiting Monday.
LPCN Need to get in before market open.
Time to go balls deep on something balls related. LPCN (Lipocene) and ATRS (Antares Phama) FDA approval decision due on Monday, but it has already been approved. Seems like a no brainer. Think with your balls guys. >FDA decision on TLANDO as oral testosterone replacement therapy in adult males for conditions associated with hypogonadism. >FDA granted tentative approval for Tlando on Dec.8, 2020 >Lipocine licensed the exclusive U.S. rights for TLANDO to Antares Pharma in Oct.2021 Tentative approval >"(also known as โTAโ) is a notification granted by the FDA if an ANDA meets the substantive requirements for approval, but cannot obtain final approval for marketing due to unexpired patents or exclusivities. So hoping Monday for a quick earner on the news. Hope to see either or both on the Finviz homepage Monday open. Heavily weighted towards LPCN since they seem to be the ones making all the licensing money.
LPCN I bought it a few months ago to practice selling covered calls. I bought at like $1.22 or something and sold enough $1.50 calls that always expired worthless to get my cost basis down to $0.99. But for some reason the calls for March were only for $2.50, $5, or $7 and no one was buying them, so I was just sitting in the shares. And all of a sudden this past week or two the price has been climbing, currently at $1.85, and people are talking like it may go to $3 or even $6 after they get some FDA approval next week. Been wild. lol
Going half balls deep on ATRS and LPCN. FDA approval decision due on Monday. >FDA decision on TLANDO as oral testosterone replacement therapy in adult males for conditions associated with hypogonadism. Just looking for a lottery ticket.
 LPCN breakout soon. Lipocine currently priced at $1.80 a share. A month and a half ago was at $0.89. Has FDA approval for TLANDO March 28th as catalyst 1 and then NASH news as catalyst two with direct access to fast tracking with the FDA. It is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. TLANDO has gotten tentative FDA approval back in December of 2020. The reason why it is tentative is because a Company named Clarus had a patent on the same type of drug so the FDA said they cannot sell until Clarusโ patent expired which is March 28th. LPCN has 4 other drugs that are in the pipeline that have yielded great results another form of TLANDO, NASH and are on the ending phases sometime in June. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth ALOT of good going on with this company and in my opinion very undervalued. Zachโs PT has it at $10.00 with a strong buy rating HC wraithwright has it at a buy at $3.00 Landenburg Thalm has it at a buy at $3.00 Check it out [LPCN research and rating](https://www.zacks.com/stock/research/LPCN/stock-style-scores) US PATENT APPROVED APRIL 12 2021 PATEL HAS ANNOUNCED A PARTNERSHIP WITH ANTRES. This company has very low debt as well and a lot of cash and revenue to keep it going.
LPCN been steady climbing throughout all these swings snd volatility. Unphased just walking up a staircase.
LPCN has been rallying lately. Might be a good swing play
Bought into LPCN at very cheap eyeing this day for FDA approval. Really love the potential growth of hormone therapy especially for men with low t levels as they age. I think itโs a potential boom industry and Iโm really interested in it so I made moves to invest in it and watching it go up some is great.
$LPCN is supposed to have a catalyst on Friday but who knows... (what, am I rattled by these last few days? noooo)
Want super high risk, high reward? LPCN and CBDD.
Most likely to succeed: NAKD Maybe: LPCN Maybe: SESN
Failed January trade. LPCN is down 40% since the big January DD that got everyone hooked. https://www.reddit.com/r/pennystocks/comments/l0lbo2/in\_depth\_lpcn\_dd\_next\_catalyst\_huge\_upside/
LPCN I bought a nice amount at $1.10 it spiked up and then came back down. It's products are developed to help people with various degrees of lowered hormones. They have a treatment that could prolong life with people with liver issues. One of there products have been FastTracked by the FDA, not some guy pumping a stock on YouTube... Yes the Federal Drug Administration, has fastracked; LPCN 1144 An oral prodrug of bioidentical testosterone being developed for pre-cirrhotic NASH. ***Check out there website: https://www.lipocine.com/ My strategy using some of my profits from ILUS and putting into LPCN. Once a drug receivesย Fast Trackย designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients. ย